Trials / Recruiting
RecruitingNCT06623136
A Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
An Open-label, Multicenter, Single-arm Phase 2 Study of ES102 in Combination With Toripalimab in Subjects With Advanced Non-small Cell Lung Cancer
- Status
- Recruiting
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Elpiscience (Suzhou) Biopharma, Ltd. · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK) and immunogenicity of ES102 in combination with Toripalimab in subjects with advanced non-small cell lung cancer (NSCLC).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | ES102 | ES102 is administered via intravenous infusion, once every 21 days. |
| DRUG | Toripalimab | Toripalimab is administered via intravenous infusion, once every 21 days. |
Timeline
- Start date
- 2025-04-30
- Primary completion
- 2027-02-28
- Completion
- 2027-12-31
- First posted
- 2024-10-02
- Last updated
- 2025-09-26
Locations
9 sites across 1 country: China
Source: ClinicalTrials.gov record NCT06623136. Inclusion in this directory is not an endorsement.